ALNY vs GILD · P/E 76, rev $1.29B vs P/E 18, rev $7.80B
Alnylam Pharmaceuticals Inc (ALNY) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ALNY and GILD stock pages for the full models.
Not investment advice.